AnaemiaNCT07912697
Triple Outcome Evaluation of Red Teff Intervention for Infant Anemia, Environmental Health, and Economic Feasibility in Ethiopia: A Self-controlled Pre-post Study
A study testing Red teff (Eragrostis teff) porridge in people with Anaemia, run by Debre Markos University at 1 site in Ethiopia.
Trial summary
Background. Childhood anemia affects more than 40% of under-five children in Ethiopia, where iron supplementation has achieved limited success and locally grounded, sustainable strategies are needed. Red teff (Eragrostis tef) is an iron-rich, gluten-free staple crop. Read more about this study
- Who is it for?
- Ages 6 to 59 months
- Conditions the study is for
- Anaemia
- What is being tested?
- Red teff (Eragrostis teff) porridge
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 32 participants
- Where
- 1 siteEthiopia
- Study dates
- 9 Feb 2025to 19 Apr 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 6 to 59 months
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Chldren diagnosed with anemia.
Who cannot join
- Child who had any physical deformities ,HIV/AIDS, diabetes mellitus and cancer.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: The Epidemiology of Triple Burden of Malnutrition and Introducing Iron Dense Porridge to Prevent Iron Deficiency Anemia Among Mother-Child Pairs in Ethiopia
Background. Childhood anemia affects more than 40% of under-five children in Ethiopia, where iron supplementation has achieved limited success and locally grounded, sustainable strategies are needed. Red teff (Eragrostis tef) is an iron-rich, gluten-free staple crop. We evaluated whether a red teff porridge improves hemoglobin in anemic infants and toddlers, and quantified its cost and potential environmental impact relative to animal-source iron-rich foods.
Methods. In a self-controlled pre-post feeding trial in East Gojjam Zone, Ethiopia, anemic children received 42 g home-prepared red teff porridge providing about 77 mg iron per day for 60 days. The primary outcome, the change in hemoglobin, was analyzed with covariate-adjusted models (n = 32 after excluding one implausible value), with covariates selected on biological grounds and additionally screened by cross-validated LASSO. The cost and greenhouse-gas emissions (GHGE) of red teff were compared with beef, lamb and egg per milligram of absorbed iron and per gram of protein, with substitution and sensitivity analyses.
- Conditions
- Anaemia
- Being tested
- Red teff (Eragrostis teff) porridge
- Medical subject headings
- Anemia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Red teff (Eragrostis teff) porridgeDietary supplement
In each household, mothers/caregivers were educated how they prepare porridge made from Red teff (Eragrostis teff). For single serving a total of 50 g of red teff flour was mixed with 50 mL of water in a small plastic bowl to form a slurry, which was then set aside. In a stainless-steel pan, 50 mL of distilled water was boiled. Once the water boiled the slurry was added to the pan and cooked for 15 minutes at 90°C with continuous stirring to prevent coagulation and sticking. After cooking, the porridge was removed from the heat and prepared for child consumption.
According to the fact that non-heme iron has a bioavailability of 10-15%, and the recommended daily allowance of iron for children aged 1-3 years is 7 mg/day. In this study, children were provided with 42 g of porridge daily for 60 days.
| Study group | Role | What they receive |
|---|---|---|
| Those children whose Hgb <11 g/dL where an arm group. | Experimental | In this study, children were provided with 42 g of porridge prepared from red teff daily for 60 days Receives: Dietary Supplement: Red teff (Eragrostis teff) porridge |
What is being measured
The primary outcome is the main question the study is designed to answer.
mean Hemoglobin level of children
Measured: It was assessed after 60 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Nov 2026
- Study start9 Feb 2025
- Primary completion19 Apr 2025
- Study completion19 Apr 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for AnaemiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 32 participants (actual)
Sponsor and investigators
- Lead sponsor
- Debre Markos University
- Sponsor type
- University, hospital or other
- Collaborators
- Tsinghua University
- Responsible party
- Principal investigator, Melese Linger Endalifer, Debre Markos University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07912697
- Sponsor's protocol ID
- DebreMarkosU
- Status last verified
- Oct 2026
- First submitted
- 26 Oct 2026
- Last updated
- 3 Nov 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Epidemiology of Triple Burden of Malnutrition and Introducing Iron Dense Porridge to Prevent Iron Deficiency Anemia Among Mother-Child Pairs in Ethiopia
- ClinicalTrials.gov ID
- NCT07912697
- Acronym / sponsor ID
- DebreMarkosU
- Conditions
- Anaemia
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 32 participants (actual)
- Lead sponsor
- Debre Markos UniversityUniversity, hospital or other
- Collaborators
- Tsinghua University
- Study start
- 9 Feb 2025 (actual)
- Primary completion
- 19 Apr 2025 (actual)
- Study completion
- 19 Apr 2025 (actual)
- First posted
- 3 Nov 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Background. Childhood anemia affects more than 40% of under-five children in Ethiopia, where iron supplementation has achieved limited success and locally grounded, sustainable strategies are needed. Red teff (Eragrostis tef) is an iron-rich, gluten-free staple crop. We evaluated whether a red teff porridge improves hemoglobin in anemic infants and toddlers, and quantified its cost and potential environmental impact relative to animal-source iron-rich foods.
Methods. In a self-controlled pre-post feeding trial in East Gojjam Zone, Ethiopia, anemic children received 42 g home-prepared red teff porridge providing about 77 mg iron per day for 60 days. The primary outcome, the change in hemoglobin, was analyzed with covariate-adjusted models (n = 32 after excluding one implausible value), with covariates selected on biological grounds and additionally screened by cross-validated LASSO. The cost and greenhouse-gas emissions (GHGE) of red teff were compared with beef, lamb and egg per milligram of absorbed iron and per gram of protein, with substitution and sensitivity analyses.
Study design
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Those children whose Hgb <11 g/dL where an arm group. | Experimental | Dietary Supplement: Red teff (Eragrostis teff) porridgeIn this study, children were provided with 42 g of porridge prepared from red teff daily for 60 days |
Who may qualify
- Ages
- 6 to 59 months
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (1 listed)
- Chldren diagnosed with anemia.
Key exclusion criteria (1 listed)
- Child who had any physical deformities ,HIV/AIDS, diabetes mellitus and cancer.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Red teff (Eragrostis teff) porridgeIn each household, mothers/caregivers were educated how they prepare porridge made from Red teff (Eragrostis teff). For single serving a total of 50 g of red teff flour was mixed with 50 mL of water in a small plastic bowl to form a slurry, which was then set aside. In a stainless-steel pan, 50 mL of distilled water was boiled. Once the water boiled the slurry was added to the pan and cooked for 15 minutes at 90°C with continuous stirring to prevent coagulation and sticking. After cooking, the porridge was removed from the heat and prepared for child consumption. According to the fact that non-heme iron has a bioavailability of 10-15%, and the recommended daily allowance of iron for children aged 1-3 years is 7 mg/day. In this study, children were provided with 42 g of porridge daily for 60 days. | Dietary supplement | Those children whose Hgb <11 g/dL where an arm group. |
Primary outcome
mean Hemoglobin level of children
Time frame: It was assessed after 60 days
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Nov 2026.
- Related InfoLink provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Anaemia
RecruitingPhase 1/2
The Safety and Efficacy of Daratumumab in Patients With Refractory Aplastic Anemia
Aplastic Anemia, Refractory
Active, not recruitingPhase 1
A Study of YTS109 Cell Injection in Subjects With Relapsed/Refractory Autoimmune Hemolytic Anemia
Autoimmune Hemolytic Anemia, Anti-CD19 STAR T-cell Therapy
Not yet recruitingObservational study
Systematic Intraoperative Cell Salvage in On-Pump Cardiac Surgery Within a Mature Patient Blood Management Programme
Cardiac Surgical Procedures, Blood Transfusion
RecruitingPhase 1/2
Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
Myelodysplastic Syndromes
RecruitingObservational study
Defining the Natural History of Squamous Cell Carcinoma in Fanconi Anemia
Fanconi Anemia, Inherited Bone Marrow Failure Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Red teff (Eragrostis teff) porridge in people with Anaemia, run by Debre Markos University at 1 site in Ethiopia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 3 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Ethiopia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
mean Hemoglobin level of children (time frame: It was assessed after 60 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Nov 2026.